Anand Viswanathan, MD, PhD, Walter A. Rocca, MD, MPH and Christophe Tzourio, MD, PhD From the Department of Neurology and Clinical Trials Unit (A.V.), Massachusetts General Hospital and Harvard Medical School, Boston; Division of Epidemiology (W.A.R.), Department of Health Sciences Research and Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN; INSERM (C.T.), Unit 708 Neur
Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease A Bruandet1,2, F Richard1,2, S Bombois3,4, C A Maurage4,5, V Deramecourt3,4, F Lebert3,4, P Amouyel1,2, F Pasquier3,41INSERM, U744, Lille, France 2Institut Pasteur de Lille, Santé publique et épidémiologie moléculaire du vieillissement, Lille, France 3EA2691, Lille, Fr
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). National Cardiovascular Center, Suita, Osaka, Japan. tyamaguc@hsp.ncvc.go.jp BACKGROUND AND PURPOSE: Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the international
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
処理を実行中です
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く